Tempus Hereditary Cancer Testing
Performed by Ambry Genetics, a Tempus company
Overview
CancerNext-Expanded®
77-gene germline panel that includes genes associated with hereditary breast, ovarian, pancreatic, prostate, colorectal, endometrial, gastric, small bowel, urothelial, renal, plus an array of additional cancers.
CancerNext®
40-gene guidelines-based germline panel that includes genes associated with hereditary breast, ovarian, pancreatic, prostate, colorectal, endometrial, gastric, small bowel, urothelial, and renal cancers.
+RNAinsight®
Optional add-on for CancerNext® or CancerNext-Expanded® that analyzes RNA to support the classification and detection of DNA variants, powered by Ambry Genetics®
BRCAplus®
A guideline-based, disease-specific test option that includes 13 genes associated with hereditary breast cancer, where screening, treatment, and/or surgical intervention may be indicated.
Key features
Why hereditary cancer testing is important
Up to 10% of all cancers are associated with hereditary cancer syndromes.1
Hereditary cancer testing can help tailor cancer treatment approaches, clarify risks for additional cancers, and help determine screening and risk reduction options.
Additionally, hereditary cancer testing may help to explain the history of cancer in the family and may assist in the identification of at-risk relatives.
Confirmatory Germline Testing
CancerNext® and CancerNext-Expanded® provide validated germline testing to confirm potential germline findings identified on somatic reports.
Hereditary cancer germline testing may also be utilized to assess variants suspicious for germline presence detected on tumor only sequencing or liquid biopsy and to test for Lynch syndrome for individuals with MSI-High tumors.
Value of Germline RNA Analysis
Decreases the number of splicing variants of unknown significance.2,3
~1 in 25 positive patients may receive negative/inconclusive results without RNA analysis.4
~5% of hereditary cancer cases leverage RNA data in variant interpretation, with patients receiving DNA-only germline testing also benefiting from the technology.2
Testing Logistics
Turnaround time: CancerNext®/CancerNext-Expanded®: ~5-14 days after specimen receipt. BRCAplus®: ~4-7 days after specimen receipt
Specimen type(s): Peripheral blood (EDTA tube for DNA testing, PAXgene® blood tube for RNA analysis), saliva (Oragene®), or skin punch biopsy (cultured fibroblasts)
Genetic counseling is available (via Genome Medical) to the patient. To request a genetic counseling consultation for your patient, please submit a completed Genetic counseling referral request form to GeneticCounseling@ambrygen.com.
How to order
Ordering flexibility
Tempus offers a variety of options to customize molecular profiling for patients.
Order germline and somatic testing in combination to obtain comprehensive results
Streamlined ordering process through Tempus Hub, paper requisition, or directly from your EHR
+RNAinsight® is available as an add-on to CancerNext® or CancerNext-Expanded®
BRCAplus® is available as a standalone test or in addition with CancerNext® or CancerNext-Expanded®, offering flexibility to support time-sensitive clinical decisions
Familial variant/cascade testing is available for at-risk family members at no additional cost if ordered within 90 days of original CancerNext® or CancerNext-Expanded® report (out to third degree relatives). Must be submitted by a qualified healthcare professional.
Resources
Learn more
Financial assistance
We help provide access to our tests for all patients in financial need
Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission.
If approved, you will know immediately about the maximum out of pocket cost of your testing.
Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.
All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com. Authorization for Medical Records: Through access.tempus.com, applicants are directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.
References
- Family cancer syndromes. American cancer society. Updated September 14, 2022. Accessed March 29, 2024. https://www.cancer.org/cancer/risk-prevention/genetics/family-cancer-syndromes.html
- Horton C, Hoang L, Zimmermann H, et al. Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. JAMA Oncol. 2024;10(2):212–219.
- Karam R, Conner B, LaDuca H, et al. Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer. JAMA Netw Open. 2019;2(10).
- Horton C, Hoang L, Grzybowski J, et al.. Expanding the reach of paired DNA and RNA sequencing: results from 450,000 consecutive individuals from a hereditary cancer cohort. Oral presentation presented at: Annual Meeting of the American Society of Human Genetics; 2024 Nov 6-8; Denver, CO.
This is AI-enabled precision medicine
This is the future of healthcare.